Citrine Medicine Announces Strategic Partnership to bring Efmody® to China for Use in Adrenal Insufficiency (AI), including Congenital Adrenal Hyperplasia (CAH)

Published: May 12, 2021
 
CAMBRIDGE, Mass. and SHANGHAI, May 12, 2021 /PRNewswire/ -- Citrine Medicine, a China-based rare disease therapeutics company, today announced that it has signed a licensing agreement with Diurnal Group plc (AIM: DNL), a specialty pharmaceutical company targeting patient needs in chronic endocrine (hormonal) diseases. The deal provides Citrine with exclusive rights to develop and commercialize Efmody
® (hydrocortisone modified-release hard capsules – development name Chronocort
®) in the Greater China market. In January, Citrine signed a licensing agreement with Dirunal Group for Alkindi,
® the first preparation of hydrocortisone specifically designed for use in children suffering from pediatric adrenal insufficiency (AI) and congenital adrenal hyperplasia (CAH).

Related Keywords

Beijing ,China ,Shanghai ,Cambridge ,Cambridgeshire ,United Kingdom ,Chinese ,Melissa Bradford Klug ,Finsbury Glover Hering ,Dandan Dong ,Sarah Sutton ,Dirunal Group For Alkindi ,European Commission For Efmody ,European Medicines Agency ,Diurnal Group ,Dirunal Group ,European Commission ,Chief Business Officer ,Managing Director ,Medical Screening ,Congenital Adrenal Hyperplasia ,Adrenal Insuffiency ,United Kingdom Headquartered ,பெய்ஜிங் ,சீனா ,ஷாங்காய் ,கேம்பிரிட்ஜ் ,கேம்பிரிட்ஜ்ஷைர் ,ஒன்றுபட்டது கிஂக்டம் ,சீன ,மெலிசா பிராட்போர்டு க்லக் ,ஃபின்ஸ்பரி குளோவர் ஹெர்ரிங் ,சாரா சுட்டன் ,ஐரோப்பிய தரகு ,தலைமை வணிக அதிகாரி ,நிர்வகித்தல் இயக்குனர் ,மருத்துவ திரையிடல் ,